antipsychotic dose increase
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Nov 1, 2008 → Mar 1, 2012
NCT ID
NCT00712660About antipsychotic dose increase
antipsychotic dose increase is a pre-clinical stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00712660. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00712660 | Pre-clinical | Completed |
Competing Products
20 competing products in Schizophrenia